GenFleet Partners with Insilico for AI-based Drug Discovery

Shanghai 's GenFleet Therapeutics partnered with Insilico Medicine, a Hong Kong AI-based drug discovery company, to identify new "game-changer" drugs. GenFleet said it will add its virtual structure research platform, which explores the dynamic structure/activity relationship between target proteins and drug molecules, to the discovery process. The two companies will address significant unmet medical oncology needs including those with novel and difficult targets. One month ago, Insilico closed a $255 million Series C round. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.